CPC C12Q 1/6886 (2013.01) [A61K 39/39558 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); G01N 33/57496 (2013.01); G01N 2570/00 (2013.01); G01N 2800/52 (2013.01); G01N 2800/7028 (2013.01)] | 26 Claims |
1. A method of treating a patient with cholangiocarcinoma cancer, the method comprising the steps of:
analyzing a sample from a patient with cholangiocarcinoma cancer for a DNA translocation in chromosome 8 band 12 p;
identifying a RBPMS-NRG1 fusion event transcribed by the DNA translocation in chromosome 8 band 12 p having a breakpoint between the 5′ end of exon 5 of the RBPMS portion and the 3′ end of exon 2 of the NRG1 portion, wherein the NRG1 portion of the RBPMS-NRG1 fusion event retains a EGF-like domain on the NRG1 portion; and
administering to the patient, having the RBPMS-NRG1 fusion event, a treatment of a therapeutic agent comprising at least one EGFR inhibitor that is targeted for the EGF-like domain of the NRG1 portion of the RBPMS-NRG1 fusion event.
|